Effectiveness of the Use of the New Hemostatic Patch Hemopatch ® in Patients Undergoing Surgical Liver Resection

Surgery Clinical Trial

— HEMOPATCH  

Official title:

Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the Use of the New Hemostatic Patch Hemopatch ® in Patients Undergoing Surgical Liver Resection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02769754
• Other study ID #: HEMOPATCH
• Status: Recruiting
• Phase: Phase 3
• First received: May 6, 2016
• Last updated: February 14, 2018
• Start date: May 2016
• Est. completion date: May 2019

Study information

• Verified date: May 2016
• Source: Instituto de Investigacion Sanitaria La Fe
• Contact: Elena García
• Phone: 0034961246611
• Email: investigacion_clinica[@]iislafe.es
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective randomized study aims to determine the influence of the use of local hemostatic on the incidence of local complications derived from the edge of transection: biliary fistula or bleeding, after scheduled hepatic resection.

Description:

Achieving adequate hemostasis is a fundamental prerequisite to successfully perform any surgical procedure, but particularly in cases of visceral abdominal surgery, where a slight bleeding, apparently insignificant, can end in significant bleeding (Haas et al Clinic and Applied thombosis 2006).

Control of intraoperative bleeding is initially performed using traditional techniques such as compression, ligatures, clips, Electrocautery, or clamps. The traditional surgical techniques often fail to prevent bleeding, despite performing a careful and meticulous hemostasis.

The morbidity after elective liver surgery has been reduced in hepatobiliary surgery centers mainly after standardizing anatomical liver resections. These techniques decrease necrosis, bleeding, and the incidence of biliary fistulas (Kraus et al J Am Coll Surg 2005).

Bleeding and biliary fistula are the main determinants of postoperative liver morbidity, with an incidence around 4.2-10% and 4-17% respectively (Yamashita et al Ann Surg 2001; Jin et al World J Gastroenterology 2013).

This complication is difficult to handle especially in patients with cirrhosis or liver cancer, because of reduced platelet and blood coagulation activity (Figueras et al Ann Surg 2007).

Moreover, it is particularly difficult to determine the individual risk of rebleeding or biliary fistula during the intraoperative time.

Many adjuvant surgical hemostatic procedures have been tested in the liver: such as oxidized cellulose, absorbable sponges, fibrillar collagen, and fibrin sealants.

There is an extensive published literature reporting the use of adhesives, Sealants, and topical hemostatics in surgery. There is little doubt that the hemostatic effects of these devices produce a beneficial impact on blood loss. However, there is a wide variation in the literature results. Most of the initial clinical data were obtained in cardiovascular surgery. The only trial that has provided the most significant data in hemostatic efficacy was published by Rousou et al in J Thorac Cardiol South 1999. In this randomized multicenter study, 333 patients that underwent emergency cardiac reoperations were randomized to receive either conventional treatment with fibrinogen or other hemostatic. The 92% of the patients assigned to receive fibrin sealant had a complete hemostasis at 5 minutes, compared with the 12% of those treated with other topical hemostatic.

In clinical practice is difficult to quantify the efficacy of the topical hemostatics on hemostasis. The overall effect of perioperative blood loss can only be inferred indirectly by volume drainage and the number of transfused concentrates (Kraus et al J Am Coll Surg 2005).

The volume of blood loss during liver surgery depends on many factors: systemic coagulation, underlying disease, surgery complexity, surgeon experience, central venous pressure, and local hemodynamics.

Moreover, bile leakages are much harder to identify, define, and particularly to quantify, when compared to bleeding. The biliary system is a low pressure system (less than venous pressure). Animal studies have shown that the use of collagen adhesives is effective for preventing biliary fistulas (Wise et al Am Surg 2002).

In a cohort study of 32 adult patients, in which a right hepatic lobe Split was held, it was compared the use of Tachosil ® versus fibrin glue. The transection area was treated with fibrin glue in 16 patients and with Tachosil ® in the other 16 ones. No differences were observed regarding the need of postoperative transfusion. Nevertheless, the group of patients treated with the fibrin patch showed a significantly lower incidence of bile leakage. Those findings were justified based on the assumption that the use of a fibrin patch, according to its base rich in fibrin, prevents bile leakage, occluding the biliary radicals at the transection (Toti et al Dig Liver Dis. 2010).

The first clinical trial comparing a hemostatic patch (Tachosil ®) versus the standard surgical hemostasis with Argon was published by Frilling et al in 2005 (Frilling et al Langenbecks Arch Surg. 2005). It was observed a reduction in the intraoperative time for hemostasis and less posterior drain in the Tachosil ® group (N = 121).

In 2007, Figueras et al (Figueras et al Ann Surg 2007) published the results of a randomized clinical trial comparing the fibrin glue administration (Tissucol ® + collagen sponge) versus control in 300 patients. The results showed no differences between groups in blood loss, transfusions, and incidence of biliary fistula, and therefore it was concluded that the cessation of the use of fibrin sealant would be a justified saving cost.

In the clinical trial recently published by Moench et al (Langenbecks Arch Surg. 2014) they studied the intraoperative time of hemostasis evaluated at 3 minutes by a non-inferiority design. The collagen hemostatic agent Sangustop ® proved to be as effective as the fibrinogen and thrombin sponge Tachosil ® in times of intraoperative hemostasis (n = 128).

The different results observed among studies may be due to the diversity of the agents evaluated, the poor standardization of the application techniques, and especially by the clinical differences.

Hemopatch® is indicated as a hemostatic device in procedures when the surgical control of bleeding by pressure, ligation, or conventional methods is inefficient or impractical. It consists in a soft, thin, foldable, and flexible collagen patch derived from bovine skin, and NHS-PEG coated (pentaerythritol polyethylene glycol ether tetrasuccinimidil glutarate). The white face, which is applied on the tissue, is covered with a thin layer of NHS-PEG providing a firm adherence to it, thus sealing the bleeding surface and inducing hemostasis at the same time. Because of its flexible structure, the application of Hemopatch ® on the site to achieve hemostasis is easily controlled. The uncoated side is marked with blue squares of a biocompatible dye, to differentiate it from the coated side.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: May 2019
• Est. primary completion date: February 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Scheduled major or minor liver resection surgery by laparotomy approach.

• Age>18

• They have given their written consent voluntarily after having offered the possibility of their participation in the study.

Exclusion Criteria:

• Pregnancy and lactation

• Patients with urgent surgery

• Concomitant surgery of another organ

• Gallbladder or biliary-enteric anastomosis associated.

• ALPPS surgery (stands for Associating Liver Partition and Portal vein Ligation for Staged hepatectomy).

• Patients with liver transplantation history.

• Patients with previous liver trauma.

• Patients with congenital haematological disease involving clotting factors alteration.

• Patients with known hypersensitivity to bovine proteins and brilliant blue colorante (FD&C Nº1).

Related Conditions & MeSH terms

• Liver Damage
• Surgery

Intervention

Device:
• Hemopatch
Hemopatch will be apply once the standard surgical hemostasis is achieved.

Other:
• Control
No additional treatment will be applied after performing the usual surgical hemostasis.

Locations

Country	Name	City	State
Spain	Hospital Universitario y Politécnico La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Instituto de Investigacion Sanitaria La Fe

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bleeding	Bleeding is defined as the fall of > 3 g/dl of hemoglobin in the postoperative as compared to the baseline value after the operation (the hemoglobin level immediately after surgery) and/or any postoperative transfusion of red blood cells packages because of hemoglobin drop and/or the need for reoperation to stop the bleeding (e.g., embolization or re- laparotomy).	Day 0 to day 30 (+-10 days)
Primary	Presence of Biliary Fistula	Biliary fistula is defined as the presence of high bilirubin levels (Bilirubin> 3x in serum level measured at the same time) in the abdominal drainage, being included the need for interventional radiology due to biliary collection or a re-laparotomy due to biliary fistula (Brooke-Smith et al HPB 2015).	Day 0 to day 30 (+-10 days)
Secondary	Age		Preoperative
Secondary	Body Mass Index (BMI)		Preoperative
Secondary	Gender		Preoperative
Secondary	Medical history (heart disease, lung disease, cirrhosis)		Preoperative
Secondary	Hypertension		Preoperative
Secondary	Dyslipemia		Preoperative
Secondary	Tobacco		Preoperative
Secondary	Alcohol		Preoperative
Secondary	Characteristics of liver disease	Characteristics of liver disease: benign-malignant (source)	Preoperative
Secondary	Type of surgery	Type of surgery:Liver resection: major/minor.	On surgery
Secondary	Type of surgery	Type of surgery: Number of resected segments/type	On surgery
Secondary	Type of surgery	Type of surgery: Number-size of hemostatic patches used as well as their location	On surgery
Secondary	Need of transfusion	concentrates number	Day 0 to day 30 (+-10 days)
Secondary	Need of transfusion	blood / plasma / platelet d. intraoperative / postoperative e. blood / plasma / platelet f. concentrates number	Day 0 to day 30 (+-10 days)
Secondary	Incidence of re-interventions	Incidence of re-interventions (No / Yes / Number / match)	30 days after surgery
Secondary	Postoperative liver failure		Day 5 after surgery
Secondary	Infection or wound dehiscence		30 days after surgery
Secondary	Interventional radiology procedures	Number of interventional radiology procedures needed and findings	30 days after surgery
Secondary	Mortality	Mortality p.o. (defined as the existence of the event within 30 days p.o.).	30 days after surgery
Secondary	Hospital stay (HS)	Hospital stay (HS) defined as number of days from the preoperative admission to discharge.	Up to 30 days after surgery
Secondary	Readmissions	Readmissions (No / Yes / number of days of re-entry / Cause).	From hospital discharge to 30 days after.
Secondary	Preoperative Chemotherapy Administration	Up to 30 days after surgery	Preoperative
Secondary	immunosuppressive therapy		Preoperative
Secondary	Diuresis		Up to 30 days after surgery
Secondary	Temperature		Up to 30 days after surgery
Secondary	Blood preassure		Up to 30 days after surgery
Secondary	Concomitant medication		Up to 30 days after surgery